Nikhil A. Gopal, MD

home / authors / nikhil-a-gopal-md

Articles

Nikhil Gopal, MD, assistant professor, urology, College of Medicine, Memphis Department of Urology, The University of Tennessee Health Science Center

Dr Gopal on a Case Study of a Patient With Bladder Cancer

Nikhil A. Gopal, MD
May 16th 2024

Nikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.

Read More

Nikhil A. Gopal, MD

Dr Gopal on Future Research Directions in Non-ccRCC

Nikhil A. Gopal, MD
April 26th 2024

Nikhil A. Gopal, MD, discusses future research directions for the treatment of various renal cell carcinoma histologies.

Read More

Nikhil A. Gopal, MD

Dr Gopal on Treatment Selection in Second-Line R/R mUC

Nikhil A. Gopal, MD
April 8th 2024

Nikhil A. Gopal, MD, discusses treatment selection in second-line relapsed/ refractory metastatic urothelial cancer.

Read More

Nikhil A. Gopal, MD

Dr Gopal on the Nuances of IO/TKI Selection in Advanced RCC

Nikhil A. Gopal, MD
March 7th 2024

Nikhil A. Gopal, MD, discusses the nuances of treatment decision-making in advanced renal cell carcinoma.

Read More

Nikhil A. Gopal, MD

Dr Gopal on the Evolution of TKI/IO Combination Approaches in RCC

Nikhil A. Gopal, MD
March 7th 2024

Nikhil A. Gopal, MD, discusses the transition of treatment with TKIs to treatment with TKI/IO combinations for those with renal cell carcinoma.

Read More

Nikhil A. Gopal, MD

Dr Gopal on the Significance of the EV-302 and CheckMate 901 Trials in mUC

Nikhil A. Gopal, MD
February 29th 2024

Nikhil A. Gopal, MD, discusses how the phase 3 EV-302 and CheckMate 901 trials have advanced the treatment paradigm in metastatic urothelial cancer.

Read More

Nikhil A. Gopal, MD

Dr Gopal on the Advantages and Potential Benefit of Belzutifan in RCC

Nikhil A. Gopal, MD
February 27th 2024

Nikhil A. Gopal, MD, discusses the benefit of belzutifan for patients with renal cell carcinoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need